Should I Buy GEHC? GEHC 2026 Analysis

Should You Buy GE Healthcare Technologies Inc (GEHC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

80.650

1 Day change

-2.02%

52 Week Range

94.800

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the stock just popped ~+4.9% on earnings and is now sitting near first resistance (R1 ~84.10), where upside becomes less favorable vs. downside.
Technicals are mixed (RSI ~63, MACD still below zero), suggesting momentum can fade after the post-earnings move.
Options sentiment leans bullish (low put/call ratios, high volume), but that can be short-lived after earnings/IV reset.
Hedge funds are net sellers (selling up ~129.9% QoQ), which is a meaningful near-term overhang.
Net: Hold / do not chase here; the current setup is more “post-earnings bounce risk” than “clean breakout buy.”

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Price action: strong earnings-driven gap/pop (+4.90% regular session), now in post-market slightly off highs (~-0.56%).
MACD: histogram -0.148 (still bearish/negative), though contracting (selling pressure easing, but not yet a bullish cross).
RSI(6): 63.5 (neutral-to-warm; not oversold, so less “cheap” for a fresh entry).
Moving averages: converging (often signals consolidation/indecision rather than a clean trend).
Key levels: Pivot ~81.10 (near-term support); Resistance R1 ~84.10 then R2 ~85.96; Support S1 ~78.09.
Pattern-based outlook provided: modeled bias points to weakness over the next week (higher probability of pullback than follow-through).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/Call ratios are bullish-leaning (OI PCR 0.71; Volume PCR 0.29), implying more call interest/flow than puts.
Activity: options volume is elevated (today vs 30D avg ~166%), signaling strong post-earnings positioning.
Volatility: IV 30D ~28.6 vs HV ~26.6 (modest premium); IV rank ~15 suggests IV is relatively low vs the past year—typical after earnings (less “event juice” left).

Technical Summary

Sell

Buy

Positive Catalysts

- Q4 2025 earnings beat: Adj. EPS 1.44 vs ~1.40–1.43 expected; revenue ~$5.7B with ~4.8% organic growth / ~7% YoY growth cited.
- Stock reaction positive immediately after results (momentum/catalyst just occurred).
- Analysts recently raising price targets (supportive forward narrative).

Neutral/Negative Catalysts

- Profitability pressure: net income down ~18.3% YoY and gross margin down ~7.2% YoY in the latest quarter.
- Hedge funds are selling (selling up ~129.9% over the last quarter), which can cap rallies.
- Technical/location risk: price is near resistance after a sharp earnings move; risk of mean reversion/pullback is elevated.
- No supportive “must-buy-now” proprietary trading signal (no AI Stock Picker or SwingMax entry).

Financial Performance

Latest quarter: 2025/Q4.
Revenue: $5.698B, +7.13% YoY (solid top-line growth).
Net income: $589M, -18.31% YoY (earnings quality/profit growth weaker than revenue).
EPS: 4.55, +189.81% YoY (strong YoY EPS growth, but alongside margin/net income decline—suggests mix/one-time/timing effects worth noting).
Gross margin: 39.68%, down ~7.22% YoY (margin compression is the key fundamental negative in this print).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent tone: improving—multiple firms raised price targets and maintained positive stances.
Piper Sandler (2026-01-30): PT raised to $94 (from $91), Overweight; sees Q4 setup tilting positive.
Jefferies (2025-12-11): PT raised to $105 (from $95), Buy; cites improving fundamentals and catalyst path.
Citi (2025-12-11): PT raised to $88 (from $83), Neutral; sees sector upside but not an aggressive call.
Wall Street pros: catalyst path + steady/improving fundamentals.
Wall Street cons: not universally bullish (Neutral coverage remains) and ongoing uncertainty/catalyst contribution assumptions (per commentary).

13 Analyst Rating

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

5 Hold

0 Sell

Moderate Buy

Current: 82.310

Low

Averages

92.25

High

105

Current: 82.310

Low

Averages

92.25

High

105

Barclays

Equal Weight

maintain

$86 -> $87

AI Analysis

2026-02-06

New

Reason

Barclays

Price Target

$86 -> $87

AI Analysis

2026-02-06

New

maintain

Equal Weight

Reason

Barclays raised the firm's price target on GE HealthCare to $87 from $86 and keeps an Equal Weight rating on the shares. The company reported a solid Q4 beat and set its 2026 outlook above the Street,the analyst tells investors in a research note.

Stifel

Rick Wise

Buy

maintain

$95 -> $98

2026-02-05

New

Reason

Stifel

Rick Wise

Price Target

$95 -> $98

2026-02-05

New

maintain

Buy

Reason

Stifel analyst Rick Wise raised the firm's price target on GE HealthCare to $98 from $95 and keeps a Buy rating on the shares. The firm came away from the company's earnings call feeling "encouraged" about the "prudent" 2026 outlook.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GEHC

Unlock Now

GEHC Should I Buy

GEHC Should I Buy

Should You Buy GE Healthcare Technologies Inc (GEHC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch